Assess the Ability of MetroGel 1% to Deliver Moisture to Facial Skin After a Single Application

Galderma R&D26 enrolled

Overview

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application.

This eight-hour kinetic regression clinical study was conducted to assess the ability of MetroGel® 1% to deliver moisture to facial skin after a single application as measured by the Corneometer CM 825.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Rosacea

Interventions

Metronidazole gel 1%DRUG

Applied once to a test site on the right or left cheek (as determined by a randomization design)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of moderate to severe rosacea, defined as the presence of at least moderate erythema with telangiectasia and a minimum of two inflammatory lesions Exclusion Criteria: * Individuals with active symptoms of allergy (mild active seasonal allergies are acceptable) or atopic dermatitis

Locations (1)

Colorado Springs Research Center

Colorado Springs, Colorado, United States

Outcomes

Primary Outcomes

Six replicate Corneometer CM 825 measurements

Time frame: 8 hours

Secondary Outcomes

Adverse events

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.